VF
ORMP icon

Virtu Financial’s Oramed Pharmaceuticals ORMP Stock Holding History

Virtu Financial’s Portfolio ORMP Stock Details ORMP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-12,123
Closed -$30K – 1912
2024
Q3 		$30K Sell
12,123
-2,653
-18% -$6.47K ﹤0.01% 1082
2024
Q2 		$38K Sell
14,776
-8,389
-36% -$19.9K ﹤0.01% 941
2024
Q1 		$68K Buy
+23,165
New +$64.8K 0.01% 978
2023
Q4 		– Sell
-17,388
Closed -$45K – 1891
2023
Q3 		$45K Buy
+17,388
New +$54.8K ﹤0.01% 918
2022
Q4 		– Sell
-21,526
Closed -$139K – 2003
2022
Q3 		$139K Sell
21,526
-5,135
-19% -$41.6K 0.01% 995
2022
Q2 		$122K Buy
+26,661
New +$142K 0.01% 897
2022
Q1 		– Sell
-21,191
Closed -$303K – 1880
2021
Q4 		$303K Buy
+21,191
New +$443K 0.03% 615
2020
Q4 		– Sell
-10,450
Closed -$27K – 1696
2020
Q3 		$27K Sell
10,450
-15,272
-59% -$53.2K ﹤0.01% 897
2020
Q2 		$91K Buy
+25,722
New +$86.3K 0.01% 906

Other funds holding ORMP

BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
M
Murchinson Toronto, Ontario, Canada $791M AUM 68.08% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
RG
Rathbones Group Liverpool, United Kingdom $25B AUM 18.87% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
PLC
Peapod Lane Capital Bedford Hills, New York $122M AUM 67.29% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Virtu Financial's ORMP Position: Q4 2024 in Review

Virtu Financial sold out of Oramed Pharmaceuticals (ORMP) in Q4 2024, closing a stake of 12,123 shares — an estimated $30K sold.

Virtu Financial first reported a position in ORMP in Q2 2020 and held it in 9 quarters. The position peaked at $303K in Q4 2021. 56 funds tracked by Wall St. Rank hold ORMP as of Q4 2024.

  • Virtu Financial reported no remaining Oramed Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Virtu Financial sold 12,123 Oramed Pharmaceuticals shares in Q4 2024, an estimated $30K.
  • Virtu Financial first reported a position in Oramed Pharmaceuticals in Q2 2020 and held it in 9 quarters.
  • Virtu Financial's Oramed Pharmaceuticals position peaked at $303K in Q4 2021.
  • 56 funds tracked by Wall St. Rank held Oramed Pharmaceuticals as of Q4 2024.

Based on Virtu Financial's 13F filing for Q4 2024, filed 11 Feb 2025.